The current financial score of Praxis Precision Medicines Inc is 6.42. Its financial status is stable, and its operating efficiency is low.
The current valuation score of Praxis Precision Medicines Inc is 9.44. Its current P/E ratio is -22.33, which is -99.31% below the recent high of -0.15 and -29.23% above the recent low of -28.85.
The current earnings forecast score of Praxis Precision Medicines Inc is 8.32. The average price target is 629.21, with a high of 1201.00 and a low of 188.00.
The current price momentum score of Praxis Precision Medicines Inc is 5.21. Currently, the stock price is trading between the resistance level at 359.27 and the support level at 267.36, making it suitable for range-bound swing trading.
The current institutional shareholding score of Praxis Precision Medicines Inc is 10.00. The latest institutional shareholding proportion is 114.11%, representing a quarter-over-quarter increase of 24.71%. The largest institutional shareholder is John Hussman, holding a total of 4.20K shares, representing 0.32% of shares outstanding, with 236.15% increase in holdings.
The current risk assessment score of Praxis Precision Medicines Inc is 5.49. The company's beta value is 2.75. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.